Clinical Trial Update: Frequent, Low-Dose Erythropoietin A Mechanistic Approach to Mitigate Adverse Cardiovascular Effects of Erythropoietin [Phase 4]

View source ↗

Summary

Phase 4 clinical trial on frequent, low-dose erythropoietin to mitigate adverse cardiovascular effects; the study was terminated with results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Atherosclerosis
• Cardiovascular Disease
• Chronic Kidney Disease

Drugs mentioned

• Erythropoietin (erythropoietin)

Snippet

Sponsor: VA Office of Research and Development | Conditions: Anemia, CKD | Phase 4 | Status: TERMINATED | Results posted: 2020-08-13